Skip to main content

BE PART OF THE FUTURE OF CANCER TREATMENT

Register Now
en-GBii-CN

历史回顾

自收购ADAM与其LIGHT技术以来, Advanced Oncotherapy已经在哈雷街地段获取规划许可, 完成了招标过程, 并在LIGHT技术开发方面取得了重大的进展。

2022
  • £19 million raised in equity to 1st December
  • LIGHT accelerator has successfully generated a proton beam at 230 megaelectron volts
  • Research published in the International Journal of Medical Physics and Practice showcased the potential superiority of the LIGHT system
  • University Hospitals Birmingham NHS Foundation Trust, began the commissioning process for the treatment room
  • LIGHT system beam optimised to a sub-millimetre size and RF conditioning completed for 20 of the 21 accelerating modules
  • Significant progress with rolling, Q-submission for US FDA 510(k) approval of the LIGHT system

2021
  • £46 million raised in equity
  • Medical treatment room construction completed, and LIGHT Patient Positioning System installed at the Company's Daresbury integration site
  • Signed a Letter of Intent with Saba Partners for the proposed purchase of a three-treatment room for LIGHT system in Switzerland
  • Signed a lessor financing partnership with Kineo Finance, formerly known as DiaMedCare, providing easier access to the Company's LIGHT system through a flexible financing solution that reduces the need for large initial upfront payments from customers
  • Infrastructure in place to support assembly and testing activities; system now capable of supporting the delivery of a proton pulse every 5 milliseconds; full medical software suite integrated; successful re-certification of ISO 13485

2020
  • Business development:
    • The London Clinic selected as the operator of the Proton Centre in Harley Street, London; Advanced Oncotherapy to receive a share of the profit of the Harley Street centre in London
    • The London Clinic partners with the Cleveland Clinic in London; cancer patients to be referred to the proton therapy centre in Harley Street
    • Sale of a LIGHT system to the Mediterranean Hospital of Limassol in Cyprus; Company to receive €50m and share of profits from clinical services
    • Installation of a LIGHT system in collaboration with UHB on the UHB campus in Birmingham; revenue sharing arrangement to be implemented
  • Technical updates:
    • Manufacturing of all critical hardware for first full-energy LIGHT system completed
    • Site preparation at Daresbury ready to support the ultra-high vacuum tests and the high-voltage conditioning of the accelerating structures
    • Machine installation process optimised enabling the reduction of the start-up time for future LIGHT systems
    • First series of the magnets steering the beam towards the treatment room delivered
  • R&D partnerships:
    • LIGHT Treatment plan System software installed at the Cleveland Clinic
    • R&D Collaboration with University Hospitals Birmingham (UHB) NHS Foundation Trust
  • Funding:
    • Two equity rounds of £23 million in total
    • €20 million funding partnership with VDL Group
    • $30 million debt facility from Nerano Pharma
  •  Corporate Governance:
    • Mrs Lori Cross was appointed Non-Executive Director on the Board
    • The Company held its first web-based Investor Day

2019
  • AVO在2019年第一季度获取了ISO:13485认证
  • 2019年我们完成了1600万英镑的股权融资和1400万英镑的债务融资。
  • 公司目前专注于在2019年第三季度完成LIGHT余下加速部件的生产, 并在2020年底治疗第一名患者。

2018
  • 2018年我们完成并宣布了3700万英镑的股权投资。
  • LIGHT系统实现生产52MeV能量的质子束, 足以治疗浅表肿瘤。 
  • 英国科技设施委员会Daresbury实验室的准备工作启动, 一切按照2020年底治疗首个患者为目标进行计划。

2017
  • 在2017年, 我们完成并宣布了3320万英镑的融资, 包括1680万的股权投资和水睦衡公司1640万英镑的独家分销协议, 该协议将独家授权水睦衡公司在中国澳门台湾香港和韩国销售LIGHT系统。
  • 我们成功完成了LIGHT系统最关键三大部件：侧耦合漂移管直线加速器（SCDTL）与射频四极（RFQ）和质子源的集成与测试。
  • 与英国科技设施委员会达成协议, 在STFC科技园Daresbury实验室建立LIGHT系统的组装测试中心。

2016
  • 在伦敦与日内瓦任命关键高管与董事会成员。
  • LIGHT系统实现重要技术突破, 成功的完成了质子源与射频四极（RFQ）的集成组装和其他其他加速部件的高能量调试。
  • 与合作伙伴Thales完成了生产优化测试。
  • 通过配售和公开发售筹集了1340万英镑的总收益。
  • 获取哈雷街中心的规划许可
  • 在英国, 美国, 欧洲, 亚洲与中东地区与潜在客户进行市场协商。

2015
  • 成功从The Howard de Walden Estate获取50年的哈雷街中心租约, 第一套LIGHT系统将落户于该中心。
  • 技术开发取得进展
  • 出售非核心资产

2014
  • 与ScandiNova, VDL和东芝达成供应协议

2013
  • 通过并购ADAM SA公司, Advanced Oncotherapy的商业活动逐步发生变化。
  • 完成执行与非执行董事以及医疗顾问委员会成员的任命
  • 获取了LIGHT系统供应保证意向书

2012
  • 公司从CareCapital改名为Advanced oncotherapy, 以反映房地产业务的剥离和公司的战略调整, 旨在发展癌症诊断与治疗领域业务。这为当今的Advanced Oncotherapy发展奠定了基础。

2008
  • 世界上体积最大, 功能最强的粒子加速器大型强子对撞机（LHC）启动。参与该项目的ADAM的科学家；未来ADAM的董事长是该项目的主要研发与管理负责人。

2007
  • 医用质子直线加速LIGHT系统的前身在ADAM团队Alburto Colussi和Ugo Almaldi教授带领下完成设计与制造。

2006
  • Advanced Oncotherapy前身CareCapital公司在伦敦AIM创业板市场上市。

1994
  • CareCapital公司成立。主营业务为私有医疗地产的开发与租赁。